It was also noted that BRAF-mutant CRC had lower MPAS compared to that of melanoma and thyroid cancer (Fig. 2), which may provide some underlying mechanisms for the poorer outcomes observed in BRAF-mutant CRC patients treated with BRAF or MEK1/2 inhibitor as single agent or in combination.10,12. This evidence concerns the gene MAP2K1 and thyroid gland carcinoma.